Lucintel's latest market report analyzed that vaccine adjuvant provides attractive opportunities in infectious disease and cancer applications. The vaccine adjuvant market is expected to reach $2.6 billion by 2028 with a CAGR of 12.6%. In this market, adjuvant emulsion is the largest segment by product, whereas infectious disease is largest by application.
Download Brochure of this report by clicking on https://www.lucintel.com/vaccine-adjuvant-market.aspx
Based on product, the vaccine adjuvant market is segmented into pathogen, adjuvant emulsion, particulate, and combination. The adjuvant emulsion segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to growing number of adjuvanted vaccines across the globe.
Browse in-depth TOC on “Vaccine Adjuvant Market”
100 – Figures/Tables
150 – Pages
The Vaccine Adjuvant Market is marked by the presence of several big and small players. Some of the prominent players offering vaccine adjuvant include GlaxoSmithKline, Novavax, SPI Pharma, Agenus, CSL Limited, InvivoGen, and BrenntagBiosector.
Request Sample Report:
https://www.lucintel.com/vaccine-adjuvant-market.aspx
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.